Leerink downgraded InflaRx (IFRX) to Market Perform from Outperform with a $2 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- Largest borrow rate increases among liquid names
- Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results
- InflaRx price target raised to $8 from $3 at Cantor Fitzgerald
- InflaRx price target raised to $9 from $2 at Raymond James
- InflaRx price target raised to $7 from $3 at Oppenheimer